Pancreatitis: acute and chronic — the AU general practice guide

Pancreatitis — inflammation of the pancreas — ranges from a self-limiting episode managed with supportive care to a life-threatening emergency with multi-organ failure. In Australian general practice, the two most important roles are recognising when a patient presenting with epigastric pain requires emergency escalation, and supporting the long-term management of chronic pancreatitis once acute episodes have resolved.

eTG complete and RACGP guidance converge on the Atlanta Classification 2012, published by Banks et al. in Gut 2013, which defines acute pancreatitis as ≥2 of three criteria: (1) typical abdominal pain — epigastric, constant, often radiating to the back; (2) serum lipase or amylase at least three times the upper limit of normal; or (3) characteristic imaging findings on CT or ultrasound. Lipase is preferred over amylase — it is more specific and persists longer in the circulation.

Acute pancreatitis carries a mortality of 1–2% in mild disease and up to 30% in severe disease with persistent organ failure. Chronic pancreatitis causes irreversible structural damage — fibrosis, ductal dilation, parenchymal calcifications — producing exocrine insufficiency (steatorrhoea, malabsorption), type 3c diabetes, and chronic pain that significantly impairs quality of life. In Australia, gallstones and alcohol account for roughly 70% of all cases, making preventable and treatable causes the dominant clinical focus.

A. Core clinical — the AU general-practice framework

Recognising acute pancreatitis

The classical presentation is severe constant epigastric pain radiating to the back, with nausea, vomiting, and complete anorexia. Pain is typically worst when lying flat and partially relieved by leaning forward. Tachycardia and hypotension suggest haemoconcentration or early systemic inflammatory response. Two late signs of severe haemorrhagic or necrotising disease — Cullen’s sign (periumbilical bruising) and Grey-Turner sign (flank bruising) — are uncommon but indicate severe disease requiring immediate escalation.

If the patient is systemically unwell, haemodynamically compromised, or has clinical features suggesting severity, arrange emergency transfer rather than waiting for investigation results.

Investigations

Order serum lipase first-line (remains elevated 3–5 days after onset), FBC, electrolytes and renal function, liver function tests, serum calcium, fasting lipids, glucose, and C-reactive protein. A CRP above 150 mg/L at 48 hours strongly predicts severe disease. Haematocrit above 44% (haemoconcentration) is an early severity marker.

Imaging:

• Abdominal ultrasound first-line — identifies gallstones and biliary tree dilation; does not accurately assess the pancreas when bowel gas obscures the view.
• CT abdomen with contrast — reserved for suspected complications, unclear diagnosis, or deteriorating patients. A key principle from GESA consensus and NICE NG104: perform CT at 72 hours or later, not on day 1. Early CT systematically underestimates the extent of pancreatic necrosis and adds radiation without changing acute management.
• MRCP or EUS — for suspected biliary cause when ultrasound is inconclusive or when small stones or microlithiasis are suspected.

Severity grading (Atlanta Classification 2012)

• Mild — no organ failure, no local complications. Majority of patients. Resolves in the first week.
• Moderately severe — transient organ failure (resolving within 48 hours) or local complications (fluid collections, necrosis). Requires monitoring for progression.
• Severe — persistent organ failure beyond 48 hours. High mortality; ICU admission indicated.

Disease severity is dynamic — reassess at 48 hours.

Cause investigation

The “I GET SMASHED” mnemonic covers the major causes: Idiopathic, Gallstones, Ethanol, Trauma, Steroids, Mumps/viral, Autoimmune (IgG4-related), Scorpion, Hyperlipidaemia/Hypercalcaemia, ERCP-induced, and Drugs. Review the medication list for azathioprine, valproate, GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide), thiazides, and oestrogen-containing medications. Investigate idiopathic cases with fasting lipids, calcium, and biliary imaging; refer to gastroenterology for recurrent episodes.

B. Management and evidence

Fluid resuscitation

eTG, ACG guidelines, and GESA recommend Hartmann’s solution (Ringer’s lactate) over normal saline — evidence shows reduced systemic inflammatory response syndrome and lower rates of hyperchloraemic acidosis. However, the WATERFALL randomised trial (NEJM 2022) found that aggressive high-volume fluid resuscitation was not superior to moderate resuscitation in mild acute pancreatitis and may worsen outcomes through fluid overload. Current guidance: titrate to clinical targets — urine output ≥0.5 mL/kg/hour, MAP ≥65 mmHg, and a falling haematocrit and lactate — rather than giving fixed-rate high-volume infusions.

Analgesia and antiemetics

Opioid analgesia (morphine, fentanyl) is appropriate. The historical concern that morphine worsens pancreatitis through sphincter of Oddi spasm has not been supported by clinical evidence and should not deter its use. Provide regular antiemetics.

Enteral nutrition

The paradigm has shifted from nil by mouth and total parenteral nutrition to early enteral feeding. Multiple randomised trials and Cochrane reviews confirm that enteral feeding within 24–48 hours reduces infectious complications, reduces hospital length of stay, and reduces mortality. Oral feeding is tried first; nasogastric tube feeding is equally effective as nasojejunal for most patients (contra older teaching). Total parenteral nutrition is reserved for the minority in whom enteral feeding is genuinely not possible.

Antibiotics

Prophylactic antibiotics for acute pancreatitis have no benefit and are not recommended by eTG or NICE NG104. Antibiotics are indicated only for proven infection — cholangitis, infected pancreatic necrosis (suggested by gas bubbles in necrotic tissue on CT, or positive fine-needle aspirate culture), or another confirmed extra-pancreatic infection.

Cholecystectomy and ERCP

Same-admission cholecystectomy for mild acute gallstone pancreatitis is now standard, supported by the PONCHO trial (Lancet 2015), which demonstrated significant reduction in recurrent biliary events without an increase in surgical complications when cholecystectomy was performed during the index admission.

ERCP is indicated within 24 hours only for acute cholangitis or persistent biliary obstruction. It is not indicated for uncomplicated acute gallstone pancreatitis and carries a 3–10% risk of post-ERCP pancreatitis.

C. Chronic pancreatitis

Chronic pancreatitis results from recurrent or sustained pancreatic injury, most commonly from sustained alcohol use or genetic predisposition (PRSS1, SPINK1, CFTR mutations). Smoking significantly accelerates progression and is independently disease-modifying.

Exocrine insufficiency: Steatorrhoea — pale, bulky, oily, malodorous stools — develops when over 90% of exocrine function is lost. Associated malnutrition, weight loss, and deficiencies of fat-soluble vitamins A, D, E, and K are common. Diagnosis is confirmed by faecal elastase-1 below 200 μg/g.

Pancreatic Enzyme Replacement Therapy (PERT): This is the cornerstone of exocrine insufficiency management. Per AMH and NPS MedicineWise: Creon (PBS Authority Required) is dosed at 25,000–75,000 lipase units with main meals and 10,000–25,000 units with snacks, taken during (not before or after) meals for optimal mixing with food. Titrate by symptom response and weight.

Type 3c diabetes: Endocrine insufficiency develops in a significant proportion of chronic pancreatitis patients. Type 3c differs fundamentally from type 1 and type 2 — both insulin and glucagon are deficient, making hypoglycaemia more severe and recovery from hypoglycaemia more difficult. Specialist endocrinology input is essential.

Pain management: Chronic abdominal pain is the dominant quality-of-life burden. Management is multidisciplinary — analgesic ladder, coeliac plexus block (interventional radiology or EUS-guided), pancreatic duct stenting, and surgery (Frey, Beger, or total pancreatectomy with islet autotransplantation for selected patients).

Disease-modifying measures: Alcohol cessation and smoking cessation are the only interventions proven to slow progression. Both should be addressed at every clinical encounter without exception.

Pancreatic cancer risk: The risk of pancreatic adenocarcinoma is elevated in hereditary pancreatitis and in longstanding chronic pancreatitis. Suspect pancreatic cancer in any patient over 50 years with new-onset diabetes or unexplained weight loss, particularly with a background of chronic pancreatitis or a family history of pancreatic, breast, or ovarian cancer.

D. Australian operations

MBS items relevant to pancreatitis include GP consultations (23, 36, 44), specialist gastroenterology or hepatobiliary surgery consultations (132, 133), CT abdomen with contrast (56401), CT pancreatic protocol (56501), MRCP (63507), ERCP (56522/56524), endoscopic ultrasound (30447), and image-guided drainage (30443).

PBS-listed medications:

• Pancreatic Enzyme Replacement Therapy (Creon) — Authority Required (Streamlined) for documented exocrine pancreatic insufficiency. Available in 10,000, 25,000, and 40,000 lipase unit capsule strengths.
• Opioids for pain — General Schedule for acute pain; Authority Required for chronic non-cancer pain, subject to SafeScript (Real-Time Prescription Monitoring) requirements.
• Insulin for type 3c diabetes — Authority Required.

Specialist referral pathways: Acute severe pancreatitis → emergency department, surgical or gastroenterology inpatient team. Gallstone pancreatitis → hepatobiliary surgeon for cholecystectomy planning (same admission for mild disease). Chronic pancreatitis → gastroenterologist (ERCP, endoscopic procedures), pain medicine, endocrinology (type 3c diabetes), dietitian, and addiction medicine where relevant.

Australian patient resources: PanKind provides patient education for pancreatic conditions. The Pancreatic Society of Australia and New Zealand (PSANZ) supports clinical guidelines. HealthDirect and Better Health Channel offer general consumer-level information.

E. Special populations

Pregnancy: Acute pancreatitis in pregnancy is most commonly due to gallstones. Outcomes for mild disease are generally comparable to non-pregnant patients, but severe pancreatitis carries significant foetal risk. MRCP is preferred over ERCP when biliary imaging is needed. Laparoscopic cholecystectomy can be performed safely in the second trimester if clinically indicated.

Young adults with recurrent pancreatitis: Hereditary pancreatitis (PRSS1 mutations) presenting as recurrent episodes in young people without identifiable cause should prompt genetic testing and referral to a specialist centre for genetic counselling and long-term pancreatic cancer surveillance planning.

Older adults: Physiological reserve limitations make older patients more vulnerable to severe disease and more sensitive to fluid overload. Fluid resuscitation requires more careful titration. Post-ERCP pancreatitis risk is higher in older patients.

People with alcohol use disorder: Highest risk of recurrent acute pancreatitis progressing to chronic disease. Concurrent nutritional deficiencies — thiamine, B12, folate, magnesium — require attention alongside acute pancreatitis management. Brief intervention and referral to alcohol and drug services is integral, not optional.

Patients on GLP-1 receptor agonists: If a patient on semaglutide, liraglutide, tirzepatide, or a related agent develops typical pancreatitis features, suspend the medication during the acute episode. The TGA notes this signal in prescribing information; reassess the benefit-risk balance before restarting.

When to escalate

Arrange emergency transfer for:

• Haemodynamic instability (hypotension, tachycardia, altered consciousness)
• Suspected severe pancreatitis — high BISAP or modified Glasgow score at 48 hours, persistent organ failure
• Features of acute cholangitis (Charcot’s triad: fever, jaundice, right upper quadrant pain)
• Suspected infected pancreatic necrosis
• Acute pancreatitis in pregnancy with systemic compromise
• Inability to tolerate any fluid or food in the context of ongoing pain

Routine referral to gastroenterology or hepatobiliary surgery for:

• All gallstone pancreatitis for cholecystectomy planning
• Recurrent or idiopathic pancreatitis — exclude ampullary or pancreatic tumour
• Chronic pancreatitis for multidisciplinary management
• New-onset diabetes in a patient over 50 with weight loss — consider pancreatic malignancy

What this article is and is not

This is general health information drawn from current Australian general practice guidelines — Therapeutic Guidelines, GESA, RACGP, AMH, NPS MedicineWise, and landmark trials including the Atlanta Classification, PONCHO, and WATERFALL. It is not personal medical advice and does not create a doctor–patient relationship. Specific treatment decisions — medication choices, referral timing, investigation sequencing — are made with your own GP and treating clinicians.

For patient resources: PanKind, HealthDirect, Better Health Channel. In severe acute pain: call 000 or go to the nearest emergency department.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Pancreatitis
2. RACGP — Pancreatitis in general practice
3. GESA — Pancreatitis management consensus
4. Pancreatic Society of Australia and New Zealand (PSANZ)
5. NPS MedicineWise
6. Australian Medicines Handbook
7. NICE NG104 — Pancreatitis
8. ACG 2013 — Acute pancreatitis management guideline
9. Banks et al. — Atlanta Classification 2012 (Gut 2013)
10. WATERFALL trial — Fluid resuscitation in acute pancreatitis (NEJM 2022)
11. PONCHO trial — Same-admission cholecystectomy (Lancet 2015)
12. Cochrane Library — Enteral nutrition in acute pancreatitis
13. TGA — GLP-1 receptor agonist prescribing information
14. PanKind — Pancreatic Cancer Foundation of Australia
15. HealthDirect — Pancreatitis
16. Better Health Channel — Pancreatitis